[an error occurred while processing this directive] | [an error occurred while processing this directive]
Efficacy of intracavitary brachytherapy for recurrent esophageal cancer after radiotherapy
Sun Yunchuan,Tian Dandan,Bi Jianqiang,Yuan Xiangkun,Shi Fumin,Hu Zhiwei,HuJianwei,Wang Junjie
Department of Radiotherapy,Cangzhou Integrated Traditional Chinese and Western Medicine Hospital,Cangzhou 061000,China (Sun YC,Tian DD,Bi JQ,Yuan XK,Shi FM,Hu ZW,Hu JW); Third Affiliated Hospital of Peking University,Beijing 100191,China (Wang JJ)
Abstract Objective To discuss the preliminary efficacy and adverse reactions of intracavitary brachytherapy in the treatment of loco-regional recurrent (LR) esophageal cancer after radiotherapy. Methods Iridium-192 brachytherapy was used to carry out intracavitary radiotherapy for 18 patients with LR esophageal cancer after initial radiotherapy from 2009 to 2013. A total irradiation dose of 16-30 Gy was given in 4-6 fractions (4-5 Gy per fraction). Intracavitary irradiation covered the lesion plus 1.0 cm upper and lower margins. The zero reference point was 10 mm far from the axis. Short-term efficacy, local control (LC) rate, overall survival (OS) rate, and adverse reactions were evaluated. Results In the 18 patients, the follow-up rate was 100%;the overall response rate was 94%,with a complete response rate of 3/18, a partial response rate of 14/18, and a no response rate of 1/18. In 16 patients with clinical symptoms on admission, 13 showed remission (6 had symptoms disappearing and 7 had symptoms alleviated), 2 remained the same, and 1 got worse after treatment, yielding an overall clinical remission rate of 81%. In all the 18 patients, 6 patients had grade ≥2 radiation esophagitis (RE), consisting of 4 with grade 2 RE and 2 with grade 3 RE.One patient with esophageal stricture at 5 months after radiotherapy received gastric fistula surgery. The median time to LC was 14 months (3-38 months). The 1-, 2-, and 3-year LC rates were 72%, 44%, and 33%, respectively. The 1-, 2-, and 3-year OS rates were 61%, 22%, and 17%, respectively. The median OS time was 12 months (5.5-45.0 months). Fourteen deaths occurred in those patients, consisting of 12 cancer-related deaths and 2 non-cancer-related deaths. Conclusions Intracavitary brachytherapy achieves satisfactory efficacy and significantly improves the symptoms in the treatment of LR after radiotherapy for esophageal cancer.
Sun Yunchuan,Tian Dandan,Bi Jianqiang et al. Efficacy of intracavitary brachytherapy for recurrent esophageal cancer after radiotherapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(12): 1305-1309.
Sun Yunchuan,Tian Dandan,Bi Jianqiang et al. Efficacy of intracavitary brachytherapy for recurrent esophageal cancer after radiotherapy[J]. Chinese Journal of Radiation Oncology, 2016, 25(12): 1305-1309.
[1] 谭立君,刘晓,肖泽芬,等.592例食管癌3DRT的预后分析[J].中华放射肿瘤学杂志,2015,24(1):10-14.10.3760/cma.j.issn.1004-4221.2015.01.004. Tan LJ,Liu X,Xiao ZF,et al. Analysis of outcomes and prognostic factors in 592 esophageal cancer patients treated with three-dimensional radiotherapy[J].Chin J Radiat Oncol,2015,24(1):10-14.10.3760/cma.j.issn.1004-4221.2015.01.004. [2] 殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2008:562-563. Yin WB,Yu ZH,Xu GZ,et al. Radiation oncology[M].4th ed. Beijing:Pecking Union Medical College Press,2008:562-563. [3] Zhou ZG,Zhen CJ,Bai WW,et al. Salvage radiotherapy in patients with local recurrent eso-phageal cancer after radical radiochemotherapy[J].Radiat Oncol,2015,10:54.10.1186/s13014-015-0358-z. [4] 务森,陈明耀,雒建超,等.食管癌根治性放化疗局部失败后挽救性手术的安全性和疗效[J].中华医学杂志,2013,93(37):2976-2978.10.3760/cma.j.issn.0376-2491.2013.37.016. Wu S,Chen MY,Luo JC,et al. A retrospective study on salvage surgery after local failure of definitive chemoradiotherapy for esophageal carcinomas[J].Natl Med J China,2013,93(37):2976-2978.10.3760/cma.j.issn.0376-2491.2013.37.016. [5] Tachimori Y.Role of salvage esophagectomy after definitive chemoradiotherapy[J].Gen Thorac Cardiovasc Surg,2009,57(2):71-78.10.1007/s11748-008-0337-5. [6] Morita M,Kumashiro R,Hisamatsu Y,et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy[J].J Gastroenterol,2011,46(11):1284-1291.10.1007/s00535-011-0448-0. [7] Nonoshita T,Sasaki T,Hirata H,et al. High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal Cancer[J].Radiat Med,2007,25(8):373-377.10.1007/s11604-007-0152-4. [8] Folkert MR,Cohen GN,Wu AJ,et al. Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients[J].Brachytherapy,2013,12(5):463-470.10.1016/j.brachy.2012.12.001. [9] Kam SWH,Rivera S,Hennequin C,et al. Salvage high-dose-rate brachytherapy for esophageal cancer in previously irradiated patients:a retrospective analysis[J].Brachytherapy,2015,14(4):531-536.10.1016/j.brachy.2015.02.392. [10] Gaspar LE,Nag S,Herskovic A,et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical research committee,American Brachytherapy Society,Philadelphia,PA[J].Int J Radiat Oncol Biol Phys,1997,38(1):127-132.10.1016/S0360-3016(97)00231-9. [11] Akagi Y,Hirokawa Y,Kagemoto M,et al. Fractionation of high dose rate intraluminal brachytherapy following external beam irradiation for superficial esophageal cancer[J].J Jpn Soc Ther Radiol Oncol,1997,9:99-106. [12] 陈东福,杨宗贻,苗延浚,等.腔内照射放疗后LR的食管癌[J].中华放射肿瘤学杂志,1993,2(2):81-83. Chen DF,Yang ZY,Miao YJ,et al. Intracavitary micro-selection high dose rate (MSH) radiotherapy of post-irrapiation recurrent esophagral cancer[J].Chin J Radiat Oncol,1993,2(2):81-83. [13] Bao Y,Liu SL,Zhou QC,et al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma:clinical efficacy and failure pattern[J].Radiat Oncol,2013,8:241.10.1186/1748-717X-8-241. [14] 沈文斌,祝淑钗,万钧,等.42例放疗后复发食管癌三维适形放疗的疗效分析[J].中华放射肿瘤学杂志,2010,19(2):111-114.10.3760/cma.j.issn.1004-4221.2010.02.007. Shen WB,Zhu SC,Wan J,et al. Three-dimensional conformal radiotherapy for loco-regionally recurrent esophageal cancer after initial radiotherapy[J].Chin J Radiat Oncol,2010,19(2):111-114.10.3760/cma.j.issn.1004-4221.2010.02.007. [15] Maingon P,D’Hombres A,Truc G,et al. High dose rate brachytherapy for superficial cancer of the esophagus[J].Int J Radiat Oncol Biol Phys,2000,46(1):71-76.10.1016/S0360-3016(99)00377-6. [16] Fabrin MG,Perrone F,De Liguoro M,et al. A single-institutional brachytherapy experience in the management of esophageal cancer[J].Brachytherapy,2010,9(2):185-191.10.1016/j.brachy.2009.08.006. [17] 罗宏涛,王小虎,魏世鸿,等.外照射放疗联合腔内近距离放疗治疗食管癌的系统评价[J].中华肿瘤防治杂志,2010,17(20):1665-1668. Luo HT,Wang XH,Wei SH,et al. Systematic review of external beam radiotherapy plus brachytherapy in treatment of patients with inoperable esophageal cancer[J].Chin J Cancer Prev Treat,2010,17(20):1665-1668. [18] Muijs CT,Beukema JC,Mul VE,et al. External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma[J].Radiat Oncol,2012,102(2):303-308.10.1016/j.radonc.2011.07.021. [19] Gava A,Fontan L,Bolner A,et al. High-dose-rate brachytherapy in esophageal carcinoma:the Italian experience[J].Radiol Med,1996,91(1-2):118-121.
2016, Vol. 25 
